Drug-Related Side Effects and Adverse Reactions Clinical Trial
Official title:
The Therapeutic Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors
The purpose of this study is to evaluate the therapeutic efficacy of topical EGF cream for dermatologic adverse events related to EGFR inhibitors.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Patients who received EGFR inhibitors (gefitinib, erlotinib, afatinib, cetuximab, etc.) for malignant tumors - Patients with EGFR inhibitor-associated skin reactions: National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE V4.03) Grade 2, 3 Patients - Patients who can understand and follow the protocol - Patients who spontaneously agreed to the study Exclusion Criteria: - NCI-CTCAE grade 4 patients requiring systemic drug therapy - Those with a history of antibiotic treatment, local and systemic steroid therapy within 4 weeks for reasons other than EGFR inhibitors - Patients with existing acne history - Patients who have already received anti-EGFR therapy |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | St. Vincent's Hospital | Suwon | Gyeonggi-do |
Lead Sponsor | Collaborator |
---|---|
The Catholic University of Korea |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change of severity of acneform eruption induced by EGFR inhibitors | To evaluate the severity of acneiform eruption, the investigators take a photograph of full face. The number of inflammatory and noninflammatory lesions will be counted and accessed the severity based on the Korean Acne Grading System(KAGS). | Baseline, 1 week, 2 weeks, 4 weeks | |
Secondary | change of skin hydration | Skin hydration is measured with Corneometer® (CM820/825; C-K Electronics, Cologne, Germany). It shows the skin moisturizing condition in arbitrary units(AU) and the unit is from 0 to 220. |
Baseline, 1 week, 2 weeks, 4 weeks | |
Secondary | change of sebum production | Sebum production is measured with Sebumeter® (SM815; C-K Electronics, Cologne, Germany). It measured at forehead, cheek and chin, presented as ?/?. |
Baseline, 1 week, 2 weeks, 4 weeks | |
Secondary | Investigator's global assessment score | Investigator's global assessment (IGA) Score : It will be assessed as a 5-point scale (-1 = worsen, to 3 = marked improvement). | Baseline, 1 week, 2 weeks, 4 weeks | |
Secondary | Patient's global assessment score | Patient's global assessment (PGA) score will be assessed as a 5-point scale (-1 = worsen, to 3 =marked improvement). | Baseline, 1 week, 2 weeks, 4 weeks | |
Secondary | The side effects of product | It will be assessed by patient-report. | Baseline, 1 week, 2 weeks, 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Recruiting |
NCT05202964 -
Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)
|
||
Completed |
NCT04597593 -
Association Between Genetic Variant Scores and DOACs (DARES2)
|
||
Recruiting |
NCT05096338 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
|
||
Recruiting |
NCT05078190 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
|
||
Completed |
NCT02457039 -
Acupuncture Prevents Chemobrain in Breast Cancer Patients
|
N/A | |
Completed |
NCT02779530 -
CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs
|
Phase 4 | |
Recruiting |
NCT03051880 -
Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors
|
N/A | |
Completed |
NCT02482025 -
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
|
N/A | |
Not yet recruiting |
NCT03147157 -
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
|
N/A | |
Recruiting |
NCT03156348 -
Impact of Clinical Pharmacist on Adverse Drug Events in Older Adults
|
N/A | |
Recruiting |
NCT03501108 -
Discontinuation of Long-term Medications in Older People Entering Nursing Home Care
|
N/A | |
Recruiting |
NCT06427317 -
Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
|
||
Completed |
NCT03227653 -
Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV
|
||
Completed |
NCT03177174 -
Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma
|
N/A | |
Recruiting |
NCT04077281 -
Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions
|
N/A | |
Not yet recruiting |
NCT05247814 -
Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
|
||
Recruiting |
NCT03938597 -
Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers
|
||
Recruiting |
NCT06291688 -
Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability
|
N/A | |
Active, not recruiting |
NCT02119078 -
Acute Care for Elders (ACE) Program at OHSU Hospital
|
N/A |